Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, July 2000, p. 1796-1802, Vol. 44, No. 7
Ohio State University,
Columbus,1 and Mt. Sinai Medical Center,
Cleveland,4 Ohio; Albany Medical
College, Albany,2 Pfizer Pharmaceutical
Group, New York,3 Winthrop Hospital,
Mineola,10 and Millard Fillmore
Suburban Hospital, University at Buffalo,
Buffalo,11 New York; University of
Chicago, Chicago, Illinois5; Salt Lake
Utah Research Project, Salt Lake City,
Utah6; Temple University, Philadelphia,
Pennsylvania7; University of Texas
at San Antonio, San Antonio, Texas8; and
University of Kentucky, Lexington,9
and University of Louisville,
Louisville,12 Kentucky
Received 7 December 1999/Returned for modification 17 February
2000/Accepted 29 March 2000
The purpose of this study was to evaluate intravenous (i.v.)
azithromycin followed by oral azithromycin as a monotherapeutic regimen
for community-acquired pneumonia (CAP). Two trials of i.v. azithromycin
used as initial monotherapy in hospitalized CAP patients are
summarized. Clinical efficacy is reported from an open-label randomized
trial of azithromycin compared to cefuroxime with or without
erythromycin. Bacteriologic and clinical efficacy results are also
presented from a noncomparative trial of i.v. azithromycin that was
designed to give additional clinical experience with a larger number of
pathogens. Azithromycin was administered to 414 patients: 202 and 212 in the comparative and noncomparative trials, respectively. The
comparator regimen was used as treatment for 201 patients; 105 were
treated with cefuroxime alone and 96 were given cefuroxime plus
erythromycin. In the comparative trial, clinical outcome data were
available for 268 evaluable patients with confirmed CAP at the 10- to
14-day visit, with 106 (77%) of the azithromycin patients cured or
improved and 97 (74%) of the comparator patients cured or improved.
Mean i.v. treatment duration and mean total treatment duration (i.v.
and oral) for the clinically evaluable patients were significantly
(P < 0.05) shorter for the azithromycin group (3.6 days for the i.v. group and 8.6 days for the i.v. and oral group) than
for the evaluable patients given cefuroxime plus erythromycin (4.0 days
for the i.v. group and 10.3 days for the i.v. and oral group). The
present comparative study demonstrates that initial therapy with i.v. azithromycin for hospitalized patients with CAP is associated with
fewer side effects and is equal in efficacy to a 1993 American Thoracic
Society-suggested regimen of cefuroxime plus erythromycin when the
erythromycin is deemed necessary by clinicians.
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Clinical Efficacy of Intravenous followed by Oral Azithromycin
Monotherapy in Hospitalized Patients with Community-Acquired
Pneumonia
*
Corresponding author. Mailing address: Pfizer Inc.,
Mailstop 235/14/5, 235 East 42nd St., New York, NY 10019. Phone: (212) 733-4231. Fax: (212) 573-5916. E-mail:
Charles.knirsch{at}pfizer.com.
Members are listed in the appendix.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»